Back to search results

Investigating Brain Changes in Parkinson's Disease with [18F]DPA-714

This study is looking at how a special imaging agent called [18F]DPA-714 binds in the brains of people with early Parkinson's disease (PD) and those who are at risk (prodromal PD), as well as healthy volunteers. [18F]DPA-714 is given through an IV, and then special brain scans (PET/MRI) are done. The goal is to see if the amount of [18F]DPA-714 binding changes over 24 months in people with PD. You might be able to join if you are already part of the PPMI study as a healthy volunteer, or have prodromal PD or early PD and haven't started treatment. You'll also need specific genetic testing showing you are a "high binder" for a gene related to TSPO. The study aims to understand how this binding relates to PD progression. The current status of this study is unclear.

Study design
This is an interventional study planning to enroll 60 participants. It compares [18F]DPA-714 binding in different groups.
What's involved
You will receive an intravenous (IV) administration of [18F]DPA-714, followed by brain PET/MRI imaging. This will be done at the beginning and again after 24 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 24 months to measure changes in brain TSPO levels.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06289582

Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

Recruiting
EARLY_PHASE1Ages 18–99InterventionalDiagnostic
University of Alabama at Birmingham
~60 participants
Updated 2026-08-12 on ClinicalTrials.gov
What's tested:[F-18]DPA714 administration IV

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Measure baseline and follow up regional brain TSPO levels using [18F]DPA-714-PET in prodromal PD.
Measured over 24 months

Conditions

Parkinson Disease

Explore related trials

Parkinson DiseaseTSPO Gene

NCT06289582

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UAB

    Birmingham, Alabamastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jonathan McConathy, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Alabama at Birmingham
  • David Standaert, MD, PhD · STUDY_DIRECTOR · University of Alabama at Birmingham

Who to contact

Evan Hudson
[email protected]
205-934-6499
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

A prodromal PD and Healthy participant enrolled in PPMI Clinical protocol
A PD participant enrolled in PPMI Clinical protocol who has not started symptomatic treatment at time of enrollment or in the first 2 years of participation.
Able to provide informed consent
Must have screening genetic testing documenting high binder at the at the known TSPO gene polymorphism (rs6971)
Male or Female (Females must meet additional criteria specified below, as applicable)
Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy).
Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.
Females of childbearing potential must not be pregnant, breastfeeding or lactating.
Includes a negative urine pregnancy test prior to injection of \[18F\]DPA-714 on day of PET scan.

Exclusion

Exposure to a total effective dose equivalent of 50 millisievert (mSv) for the whole body, which is the annual limit established by the US Code of Federal Regulations , during the past year.
Any other medical or psychiatric condition or lab abnormality, which in the opinion of the Site Investigator might preclude participation.

What this trial measures

  • Measure baseline and follow up regional brain TSPO levels using [18F]DPA-714-PET in prodromal PD.24 months

    The changes over time in neuroinflammation based on TSPO will be assessed by comparing TSPO-PET imaging at baseline, 12 months and 24 months after enrollment.